Thermo Fisher Scientific: Could Its New Sanofi Site Supercharge America’s Drug Supply Chain?

Thermo Fisher Scientific reported a solid third-quarter performance for 2025, demonstrating effective operational execution and strategic management. The company’s revenue increased by 5% to $11.12 billion, with an organic growth of 3%. Adjusted operating income rose by 9% to $2.59 billion, and adjusted EPS grew by 10% to $5.79 per share. Importantly, the adjusted operating margin expanded by 100 basis points to 23.3%. Positive momentum was seen in several sectors, particularly in Pharma and Biotech, which showed mid-single-digit growth driven by strong outputs from the Bioproduction and Analytical Instruments segments. The company also saw positive sequential growth in the Industrial and Applied segment, owing to its Electron Microscopy business and research and safety market channel. However, growth in the Diagnostics and Healthcare segment was hampered by challenges in China, despite improvements in Transplant and Immunodiagnostics businesses.